Physician profile
Christopher D Bojrab
NPI 1689659013
$713,163.87
in general payments reported to CMS, 2019-2025
47 companies · $105K in 2025
The $105K reported for 2025 was more than what 99% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $86K · 2020: $50K · 2021: $54K · 2022: $82K · 2023: $200K · 2024: $136K · 2025: $105K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $243K · Consulting Fee: $116K · Honoraria: $26K · Food and Beverage: $23K · Travel and Lodging: $23K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $8,718 · Education: $318.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $242,797.25 |
| Consulting Fee | $115,957.75 |
| Honoraria | $26,464.00 |
| Food and Beverage | $23,477.54 |
| Travel and Lodging | $22,969.50 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $8,717.63 |
| Education | $317.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $150,099.88 | 2021-2025 | Vraylar, Qulipta |
| Axsome Therapeutics, INC. | $127,663.33 | 2022-2025 | Auvelity, Sunosi |
| Allergan, INC. | $70,390.76 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $69,280.66 | 2019-2025 | Austedo Xr, Austedo, Austedo Xr |
| Neurocrine Biosciences, INC. | $62,492.20 | 2019-2025 | Ingrezza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $48,190.21 | 2020-2025 | Caplyta |
| Alkermes, INC. | $42,492.14 | 2019-2025 | Lybalvi, Aristada |
| Otsuka America Pharmaceutical, INC. | $38,079.13 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Vanda Pharmaceuticals INC. | $18,833.42 | 2019-2025 | Fanapt, Hetlioz |
| Supernus Pharmaceuticals, INC. | $14,669.28 | 2021-2024 | Qelbree, Qelbree |
| Eli Lilly and Company | $12,057.75 | 2025 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $8,474.82 | 2019-2025 | |
| Noven Pharmaceuticals, INC. | $8,387.00 | 2024 | Xelstrym |
| Eisai INC. | $7,938.37 | 2020-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $7,928.93 | 2019-2024 | Trintellix |
Show all 47 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $7,842.05 | 2021-2025 | Azstarys, Azstarys |
| E.R. Squibb & Sons, L.L.C. | $4,677.39 | 2024-2025 | Cobenfy |
| Lilly USA, LLC | $3,291.61 | 2019 | |
| Sage Therapeutics, LLC | $2,100.73 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $1,594.96 | 2019-2022 | |
| Jazz Pharmaceuticals INC. | $1,311.85 | 2019-2025 | |
| Noven Therapeutics, LLC | $1,114.94 | 2023-2025 | Xelstrym |
| Janssen Pharmaceuticals, INC | $1,033.21 | 2019-2025 | Spravato |
| Ironshore Pharmaceuticals INC. | $1,006.67 | 2019-2024 | Jornay Pm |
| Bausch Health US, LLC | $357.84 | 2019-2025 | Aplenzin, Wellbutrin |
| Biohaven Pharmaceutical Holding Company LTD. | $248.25 | 2022 | |
| Lundbeck LLC | $227.04 | 2019-2023 | Rexulti |
| Neos Therapeutics, LP | $151.54 | 2019-2025 | Adzenys Xr-Odt |
| Boston Scientific Corporation | $149.68 | 2023 | |
| Adlon Therapeutics L.P. | $128.72 | 2019-2021 | |
| Harmony Biosciences LLC | $121.89 | 2021 | |
| Tris Pharma INC | $119.16 | 2019-2023 | Dyanavel Xr |
| Vertical Pharmaceuticals, LLC | $98.71 | 2019-2025 | Relexxii |
| Acadia Pharmaceuticals INC | $96.08 | 2022-2025 | Nuplazid |
| Collegium Pharmaceutical, INC. | $77.72 | 2025 | Jornay Pm |
| Almatica Pharma LLC | $64.28 | 2022-2024 | Loreev Xr |
| Currax Pharmaceuticals LLC | $58.48 | 2021-2023 | Contrave |
| Biogen, INC. | $56.85 | 2025 | Zurzuvae |
| Neuronetics, INC. | $43.87 | 2021-2024 | Neurostar Tms Therapy System |
| Arbor Pharmaceuticals, INC. | $43.29 | 2019-2020 | |
| Avadel Cns Pharmaceuticals, LLC | $43.04 | 2024 | Lumryz |
| Idorsia Pharmaceuticals US INC | $34.16 | 2023 | Quviviq |
| Indivior INC. | $26.53 | 2019 | |
| Nalpropion Pharmaceuticals LLC | $21.00 | 2019 | |
| Avanir Pharmaceuticals, INC. | $17.66 | 2019 | |
| Shire North American Group INC | $14.64 | 2019 | |
| Merck Sharp & Dohme LLC | $12.15 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Bojrab listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.